However, our study was not intended to analyze interactions with chemotherapy or targeted agents and further research is needed to determine whether the assessment of GCs in cancer-free LNs provides additive value for prediction of immunotherapy or anti-HER2 treatment response. This evidence concerns the gene ERBB2 and cancer.